DexCom (NASDAQ:DXCM) Cut to “Hold” at StockNews.com

StockNews.com lowered shares of DexCom (NASDAQ:DXCM) from a buy rating to a hold rating in a research report sent to investors on Tuesday.

Other equities analysts have also issued research reports about the stock. Piper Sandler upped their price target on shares of DexCom from $135.00 to $150.00 and gave the stock an overweight rating in a research report on Tuesday, December 19th. Raymond James upped their price target on shares of DexCom from $147.00 to $151.00 and gave the stock a strong-buy rating in a research report on Tuesday, January 23rd. Morgan Stanley upped their price target on shares of DexCom from $101.00 to $122.00 and gave the stock an equal weight rating in a research report on Monday, December 4th. Wells Fargo & Company upped their price target on shares of DexCom from $110.00 to $136.00 and gave the stock an overweight rating in a research report on Wednesday, December 13th. Finally, Royal Bank of Canada began coverage on shares of DexCom in a research report on Tuesday, March 12th. They issued an outperform rating and a $165.00 target price for the company. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, DexCom currently has an average rating of Moderate Buy and an average price target of $136.67.

DexCom Stock Down 0.6 %

DXCM stock opened at $138.70 on Tuesday. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. DexCom has a 1-year low of $74.75 and a 1-year high of $142.00. The firm has a fifty day moving average price of $125.54 and a two-hundred day moving average price of $112.03. The firm has a market cap of $53.47 billion, a price-to-earnings ratio of 105.88, a PEG ratio of 2.40 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.07. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The firm’s revenue for the quarter was up 26.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.34 earnings per share. Research analysts predict that DexCom will post 1.76 EPS for the current year.

Insider Buying and Selling at DexCom

In other news, COO Jacob Steven Leach sold 3,978 shares of the company’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $123.63, for a total value of $491,800.14. Following the transaction, the chief operating officer now owns 262,499 shares in the company, valued at approximately $32,452,751.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Sadie Stern sold 2,902 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $123.63, for a total value of $358,774.26. Following the completion of the transaction, the executive vice president now directly owns 79,051 shares of the company’s stock, valued at $9,773,075.13. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 3,978 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $123.63, for a total value of $491,800.14. Following the completion of the transaction, the chief operating officer now directly owns 262,499 shares of the company’s stock, valued at $32,452,751.37. The disclosure for this sale can be found here. In the last three months, insiders sold 183,635 shares of company stock valued at $24,020,621. 0.41% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cary Street Partners Investment Advisory LLC lifted its holdings in shares of DexCom by 11.1% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock valued at $108,000 after acquiring an additional 115 shares during the period. CX Institutional bought a new position in shares of DexCom during the fourth quarter valued at $286,000. Intelligence Driven Advisers LLC bought a new position in shares of DexCom during the third quarter valued at $525,000. EULAV Asset Management lifted its holdings in shares of DexCom by 28.1% during the third quarter. EULAV Asset Management now owns 100,000 shares of the medical device company’s stock valued at $9,330,000 after acquiring an additional 21,938 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in shares of DexCom by 10.8% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 558,500 shares of the medical device company’s stock valued at $52,108,000 after acquiring an additional 54,626 shares during the period. 97.75% of the stock is owned by institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.